Anti-HER3 monoclonal antibody patritumab sensitizes refractory …
WEBMay 11, 2015 · Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for the drug has yet to be identified.
DB-1310, an ADC comprised of a novel anti-HER3 antibody …
WEBApr 17, 2024 · DB-1310 binds HER3 via a new epitope, which is distinct from the epitope recognized by patritumab, inducing fast HER3 internalization. The binding with this novel epitope may facilitate fast up-taken of DB-1310 by HER3 + tumor cells with on-target delivery of the payload.
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, …
WEBSep 5, 2023 · The binding epitope of Ab562 was mapped to ECD1 by domain swaps of mouse HER3 (Ab562 was not cross-reactive with mouse HER3; Fig. 1A). The binding affinity measured by ELISA of Ab562 on recombinant HER3 protein was 20–30 nmol/L, compared with about 3 nmol/L for patritumab (Supplementary Fig. S1A).
10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor ...
WEBFeb 6, 2020 · 10D1F binds to a unique epitope on the HER3 dimerization interface, topologically distant from other HER3 antibodies, to inhibit heterodimerization with EGFR and HER2. A, 10D1F epitope binning, using examples of class 1 (seribantumab) and class 2 (elgemtumab) anti-HER3 antibodies.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth …
WEBOct 6, 2023 · Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study.
Patritumab Deruxtecan Demonstrated Statistically Significant ...
WEB5 days ago · Patritumab deruxtecan (HER3-DXd) is an investigational HER3 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, patritumab deruxtecan is composed of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based ...
Novel functional anti-HER3 monoclonal antibodies with potent …
WEBJan 7, 2020 · Since clinical testing of anti-HER3 monoclonal antibodies (mAbs) such as patritumab could not show remarkable effect compared with existing drugs, we generated novel mAbs against anti-HER3. Novel rat mAbs reacted with HEK293 cells expressing HER3, but not with cells expressing HER1, HER2 or HER4.
Anti-HER3 monoclonal antibody patritumab sensitizes refractory …
WEBFeb 18, 2016 · Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for ….
Novel functional anti-HER3 monoclonal antibodies with potent anti ...
WEBJan 7, 2020 · Epitope analysis of anti-HER3 rat mAbs and Patritumab. (A) Scheme for the epitope analysis of anti-HER3 rat mAbs with HER3 transfectants. (B) 3D bar graph for the binding inhibition (%) by all combinations of anti-HER3 rat mAbs.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3 …
WEBSep 10, 2023 · Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.